Treatment of bullous pemphigoid with dapsone, methylprednisolone, and topical clobetasol propionate: A retrospective study of 62 cases

Cutis

Volumn 76, Issue 3, 2005, Pages 205-209

  Schmidt, Enno ^a   Kraensel, Robert ^a   Goebeler, Matthias ^a   Sinkgraven, Ronald ^b   Bröcker, Eva B ^a   Rzany, Berthold ^b   Zillikens, Detlef ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CLOBETASOL; DAPSONE; DRUG DERIVATIVE; METHYLPREDNISOLONE;

AGED; ARTICLE; BULLOUS PEMPHIGOID; DRUG COMBINATION; FEMALE; FOLLOW UP; HUMAN; MALE; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE; REMISSION; RETROSPECTIVE STUDY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; AGED; ANTI-INFLAMMATORY AGENTS; CLOBETASOL; DAPSONE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHYLPREDNISOLONE; PEMPHIGOID, BULLOUS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 26244449650     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Yancey KB, Egan CA. Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA. 2000;284:350-356.
2. Khumalo NP, Murrell DF, Wojnarowska F, et al. A systematic review of treatments for bullous pemphigoid. Arch Dermatol. 2002;138:385-389.
3. Savin JA. The events leading to the death of patients with pemphigus and pemphigoid. Br J Dermatol. 1979;101:521-527.
4. Rzany B, Partscht K, Jung M, et al. Low serum albumin, high dosage of glucocorticosteroids, and old age are risk factors for lethal outcome in patients with bullous pemphigoid. Arch Dermatol. 2002;138:903-908.
5. Rogers RS III, Seehafer JR, Perry HO. Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol. 1982;6:215-223.
6. Wojnarowska F, Marsden RA, Bhogal B, et al. Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults, a comparative study demonstrating clinical and immunopathologic overlap. J Am Acad Dermatol. 1988;19:792-805.
7. Huilgol SC, Black MM. Management of the immunobullous disorders, I: pemphigoid. Clin Exp Dermatol. 1995;20:189-201.
8. Callot-Mellot C, Bodemer C, Caux F, et al. Epidermolysis bullosa acquisita in childhood. Arch Dermatol. 1997;133:1122-1126.
9. Powell J, Kirtschig G, Allen J, et al. Mixed immunobullous disease of childhood: a good response to antimicrobials. Br J Dermatol. 2001;144:769-774.
10. Jeffes EW III, Ahmed AR. Adjuvant therapy of bullous pemphigoid with dapsone. Clin Exp Dermatol. 1989;14:132-136.
11. Yenning VA, Millard PR, Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol. 1989;120:83-92.
12. Person JR, Rogers RS III. Bullous pemphigoid responding to sulfapyridine and the sulfones. Arch Dermatol. 1977;113:610-615.
13. Piamphongsant T. Dapsone for the treatment of bullous pemphigoid. Asian Pac J Allergy Immunol. 1983;1:19-21.
14. Bouscarat F, Chosidow O, Picard-Dahan C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol. 1996;34:683-684.
15. Hornschuh B, Hamm H, Wever S, et al. Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol. J Am Acad Dermatol. 1997;36:101-103.
16. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45:420-434.
17. Thuong-Nguyen V, Kadunce DP, Hendrix JD, et al. Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol. 1993;100:349-355.
18. Schmidt E, Reimer S, Kruse N, et al. The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol. 2001;124:157-162.
19. Gammon WR, Merritt CC, Lewis DM, et al. An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement. J Invest Dermatol. 1982;78:285-290.
20. Liu Z, Giudice GJ, Zhou X, et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest. 1997;100:1256-1263.
21. Liu Z, Shapiro SD, Zhou X, et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest. 2000;105:113-123.
22. Sitaru C, Schmidt E, Petermann S, et al. Autoantibodies to BP180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol. 2002;118:664-671.
23. Westerhof W. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol. 1989;20:458-461.
24. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346:321-327.
25. Bozeman PM, Learn DB, Thomas EL. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem Pharmacol. 1992;44:553-563.
26. Hörnsten P, Keisu M, Wiholm BE. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol. 1990;126:919-922.
27. Prussick R, Ali MA, Rosenthal D, et al. The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Arch Dermatol. 1992;128:210-213.